JPH10513551A - 被検体の磁気緩和測定での検出のための方法及び化合物並びにそれらの使用 - Google Patents
被検体の磁気緩和測定での検出のための方法及び化合物並びにそれらの使用Info
- Publication number
- JPH10513551A JPH10513551A JP8522638A JP52263896A JPH10513551A JP H10513551 A JPH10513551 A JP H10513551A JP 8522638 A JP8522638 A JP 8522638A JP 52263896 A JP52263896 A JP 52263896A JP H10513551 A JPH10513551 A JP H10513551A
- Authority
- JP
- Japan
- Prior art keywords
- relaxation
- ferromagnetic
- ferrimagnetic
- substance
- analyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000005291 magnetic effect Effects 0.000 title claims abstract description 128
- 238000000034 method Methods 0.000 title claims abstract description 96
- 238000005259 measurement Methods 0.000 title claims abstract description 83
- 238000001514 detection method Methods 0.000 title claims abstract description 22
- 150000001875 compounds Chemical class 0.000 title claims abstract description 20
- 239000007791 liquid phase Substances 0.000 claims abstract description 19
- 239000007790 solid phase Substances 0.000 claims abstract description 16
- 238000004458 analytical method Methods 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims description 83
- 239000002245 particle Substances 0.000 claims description 64
- 230000005294 ferromagnetic effect Effects 0.000 claims description 52
- 230000005293 ferrimagnetic effect Effects 0.000 claims description 45
- 239000012491 analyte Substances 0.000 claims description 37
- 239000003550 marker Substances 0.000 claims description 31
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 22
- 230000005415 magnetization Effects 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 19
- 238000002372 labelling Methods 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 102000005962 receptors Human genes 0.000 claims description 14
- 108020003175 receptors Proteins 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000011616 biotin Substances 0.000 claims description 11
- 229960002685 biotin Drugs 0.000 claims description 11
- 235000020958 biotin Nutrition 0.000 claims description 11
- 150000001720 carbohydrates Chemical class 0.000 claims description 11
- 235000014633 carbohydrates Nutrition 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 239000000556 agonist Substances 0.000 claims description 10
- 239000003302 ferromagnetic material Substances 0.000 claims description 10
- 238000000159 protein binding assay Methods 0.000 claims description 10
- 239000002902 ferrimagnetic material Substances 0.000 claims description 9
- 238000003018 immunoassay Methods 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108090001008 Avidin Proteins 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 241000238366 Cephalopoda Species 0.000 claims description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 102000053602 DNA Human genes 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 6
- 102000004895 Lipoproteins Human genes 0.000 claims description 6
- 108090001030 Lipoproteins Proteins 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 102000002045 Endothelin Human genes 0.000 claims description 5
- 108050009340 Endothelin Proteins 0.000 claims description 5
- 108010090804 Streptavidin Proteins 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 5
- 229920002477 rna polymer Polymers 0.000 claims description 5
- 230000006399 behavior Effects 0.000 claims description 4
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000000084 colloidal system Substances 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 238000003891 environmental analysis Methods 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 3
- 230000004720 fertilization Effects 0.000 claims description 3
- 230000004907 flux Effects 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 231100000027 toxicology Toxicity 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 230000036760 body temperature Effects 0.000 claims description 2
- -1 lymphokine Proteins 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 1
- 239000000523 sample Substances 0.000 description 49
- 239000000243 solution Substances 0.000 description 31
- 102000008186 Collagen Human genes 0.000 description 16
- 108010035532 Collagen Proteins 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 229920001436 collagen Polymers 0.000 description 16
- 239000000725 suspension Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 10
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 8
- 238000005070 sampling Methods 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 230000003367 anti-collagen effect Effects 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 239000004793 Polystyrene Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000005298 paramagnetic effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000005292 diamagnetic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000005405 multipole Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 description 2
- 229910000859 α-Fe Inorganic materials 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 235000021538 Chard Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940090961 chromium dioxide Drugs 0.000 description 1
- IAQWMWUKBQPOIY-UHFFFAOYSA-N chromium(4+);oxygen(2-) Chemical compound [O-2].[O-2].[Cr+4] IAQWMWUKBQPOIY-UHFFFAOYSA-N 0.000 description 1
- AYTAKQFHWFYBMA-UHFFFAOYSA-N chromium(IV) oxide Inorganic materials O=[Cr]=O AYTAKQFHWFYBMA-UHFFFAOYSA-N 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- NQNBVCBUOCNRFZ-UHFFFAOYSA-N nickel ferrite Chemical compound [Ni]=O.O=[Fe]O[Fe]=O NQNBVCBUOCNRFZ-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- AJCDFVKYMIUXCR-UHFFFAOYSA-N oxobarium;oxo(oxoferriooxy)iron Chemical compound [Ba]=O.O=[Fe]O[Fe]=O.O=[Fe]O[Fe]=O.O=[Fe]O[Fe]=O.O=[Fe]O[Fe]=O.O=[Fe]O[Fe]=O.O=[Fe]O[Fe]=O AJCDFVKYMIUXCR-UHFFFAOYSA-N 0.000 description 1
- 230000005408 paramagnetism Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/12—Measuring magnetic properties of articles or specimens of solids or fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/411—Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
- A61B5/415—Evaluating particular organs or parts of the immune or lymphatic systems the glands, e.g. tonsils, adenoids or thymus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/72—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables
- G01N27/74—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids
- G01N27/745—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids for detecting magnetic beads used in biochemical assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/806—Electrical property or magnetic property
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/916—Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/92—Detection of biochemical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/927—Diagnostic contrast agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/932—Specified use of nanostructure for electronic or optoelectronic application
- Y10S977/953—Detector using nanostructure
- Y10S977/96—Of magnetic property
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Electrochemistry (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analyzing Materials By The Use Of Magnetic Means (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.液相及び/又は固相中の被検体を定性的及び/又は定量的に検出するため の方法であって、イムノアッセイ又は他の結合アッセイにおいて同定されるべき 磁気ラベリングとして強磁性又はフェリ磁性コロイド状粒子が用いられ、そして それらの磁化の緩和が測定変数として測定されることを特徴とする方法。 2.磁気緩和測定により液相及び固相中の被検体を定量的に検出するための方 法であって、イムノアッセイ又は他の結合アッセイにおいて同定されるべき磁気 ラベリングとして強磁性又はフェリ磁性コロイド状粒子が用いられ、該粒子の測 定条件下でのブラウン(Br 徴とする方法。 3.振動数の関数として複合体磁化率を測定することにより、液相及び固相中 の被検体を定量的に検出するための方法であって、イムノアッセイ又は他の結合 アッセイにおいて同定されるべき磁気ラベリングとして強磁性又はフェリ磁性コ ロイド状粒子が用いられ、ここで測定条件下での該粒子のブラウン緩和がネール 緩和より迅速に進行することを特徴とする方法。 4.液相及び固相中の被検体を定量的に検出するための方法であって、前記被 検体に結合する構造特異的物質が、最初に、 i)強磁性又はフェリ磁性コロイド状粒子で標識され、次に、 ii)これらの標識された構造特異的物質が、測定されるべき液体の又は固定化 されたサンプルにおいて用いられ、前記測定されるべきサンプルが、外部から適 用される磁場により磁化され、そして前記外部からの場を除去した後、磁気マー カーの磁化の緩和が磁場センサーにより測定される ことを特徴とする方法。 5.液相及び固相中の被検体を定量的に検出するための方法であって、前記被 検体が、最初に、 i)強磁性又はフェリ磁性コロイド状粒子で標識され、次に、 ii)これらの磁気的に標識された被検体が、測定されるべき液体の又は固定化 されたサンプルにおいて用いられ、該サンプルに前記被検体に特異的に結合する 物質が添加され、そして前記測定されるべきサンプルが、外部から適用される磁 場により磁化され、そして前記外部からの場を除去した後、磁気マーカーの磁化 の緩和が磁場センサーにより測定される ことを特徴とする方法。 6.固相に結合した被検体を定量的に検出するための方法であって、前記被検 体に結合する構造特異的物質が、最初に、 i)測定の時間範囲において緩和する強磁性又はフェリ磁性コロイド状粒子で 標識され、それにより測定条件下でブラウン緩和がネール緩和より短い緩和時間 を有するように、前記強磁性又はフェリ磁性コロイド状粒子が選択され、次に ii)これらの磁気的に標識された物質が、測定されるべき固定化されたサンプ ルにおいて用いられ、そして前記測定されるべきサンプルが、外部から適用され る磁場により磁化され、そして前記外部からの場を除去した後、磁気マーカーの 磁化の緩和が磁場センサーにより測定され、それにより未結合の前記磁気マーカ ーに対する前記被検体に結合した前記磁気マーカーの異なる緩和挙動が分析のた めに用いられる ことを特徴とする方法。 7.測定の時間範囲において緩和する強磁性又はフェリ磁性コロイド状粒子で 同定されるべき被検体が標識され、ここで測定条件下 での前記粒子のブラウン緩和がネール緩和より短い緩和時間を有し、そして更に 、前記被検体に特異的に結合する物質が前記測定されるべきサンプルに添加され るか、又は前記被検体に特異的に結合する物質が前記サンプル中に固定化されて 存在することを特徴とする請求項6に記載の方法。 8.液相中に存在する被検体を定量的に検出するための方法であって、前記被 検体に結合する構造特異的物質が、最初に、 i)強磁性又はフェリ磁性コロイド状粒子で標識され、ここで測定条件下での 前記粒子のブラウン緩和がネール緩和より短い緩和時間を有し、次に、 ii)これらの磁気的に標識された物質が測定されるべきサンプルにおいて用い られ、そして該測定されるべきサンプルが、外部から適用される磁場により磁化 され、そして前記外部からの場を除去した後、磁気マーカーの磁化の緩和が磁場 センサーにより測定され、それにより未結合の前記マーカーに対する前記被検体 に結合した前記磁気マーカーの異なる緩和挙動が分析のために用いられる ことを特徴とする方法。 9.同定されるべき被検体が強磁性又はフェリ磁性コロイド状粒子で標識され 、ここで測定条件下での前記粒子のブラウン緩和がネール緩和より短い緩和時間 を有し、そして更に、前記被検体に特異的に結合する物質が前記測定されるべき サンプルに添加されることを特徴とする請求項8に記載の方法。 10.検出のために、振動数の関数としての複合体磁化率の測定が用いられるこ とを特徴とする請求項1又は4〜9のいずれかに記載の方法。 11.前記構造特異的物質が、抗体、抗体フラグメント、ビオチン、又はアビジ ン及びストレプトアビジンのようなビオチンに特異的 に結合する物質、レセプターに特異的に結合するアゴニストもしくはそれらのア ンタゴニスト、特異的ペプチド及び蛋白質、レセプター、酵素、酵素基質、ヌク レオチド、リボ核酸、デオキシリボ核酸、炭水化物、又はリポ蛋白質であること を特徴とする請求項1〜10のいずれかに記載の方法。 12.前記レセプターに結合するアゴニストが、サイトカイン、リンホカイン、 又はエンドセリンであることを特徴とする請求項11に記載の方法。 13.前記構造特異的物質が、105〜1015(mol/l)-1の範囲の結合定数を有する ことを特徴とする請求項11又は12に記載の方法。 14.前記構造特異的物質が、107〜1015(mol/l)-1の範囲の結合定数を有する ことを特徴とする請求項11又は12に記載の方法。 15.磁場センサーとして、超電導量子干渉計(SQUID)、誘導コイル、フラック スゲート(flux gate)磁力計、巨大磁気抵抗センサー、又は磁気抵抗性コンバー ターが用いられることを特徴とする請求項1〜14のいずれかに記載の方法。 16.測定がサンプル中の2以上の異なる被検体で行われることを特徴とする請 求項1〜15のいずれかに記載の方法。 17.識別され得るブラウン又はネール緩和時間を有する2以上の強磁性又はフ ェリ磁性物質が用いられることを特徴とする請求項16に記載の方法。 18.磁気緩和測定により、又は振動数の関数としての複合体磁化率により液相 及び固相中の被検体を定量的に検出するための化合物であって、構造特異的物質 又は同定されるべき物質との強磁性又はフェリ磁性コロイド状粒子の組合せから なることを特徴とする化合物。 19.磁気緩和測定により、又は振動数の関数としての複合体磁化 率の測定により、液相及び固相中の被検体を定量的に検出するための化合物であ って、該化合物が、構造特異的物質又は同定されるべき物質との強磁性又はフェ リ磁性コロイド状粒子の組合せからなり、ここで測定条件下での前記粒子のブラ ウン緩和が、ネール緩和より迅速に進行することを特徴とする化合物。 20.前記強磁性及びフェリ磁性物質が、1〜400nm の範囲の粒径を有すること を特徴とする請求項1〜17のいずれかに記載の方法。 21.前記強磁性及びフェリ磁性物質が、1〜100nm の範囲の粒径を有すること を特徴とする請求項1〜17のいずれかに記載の方法。 22.前記強磁性及びフェリ磁性物質が、オリゴマーもしくはポリマー炭水化物 、蛋白質、ペプチド、ヌクレオチド、及び/又は脂質から作られたシェルで安定 化されることを特徴とする請求項1〜17のいずれかに記載の方法。 23.前記強磁性及びフェリ磁性物質が、1〜400nm の範囲の粒径を有すること を特徴とする請求項18又は19に記載の方法。 24.前記強磁性及びフェリ磁性物質が、1〜100nm の範囲の粒径を有すること を特徴とする請求項18又は19に記載の方法。 25.前記強磁性及びフェリ磁性物質が、オリゴマーもしくはポリマー炭水化物 、蛋白質、ペプチド、ヌクレオチド、界面活性剤、ポリマー及び/又は脂質から 作られたシェルで安定化されることを特徴とする請求項18,19,23又は24のいず れかに記載の方法。 26.前記構造特異的物質が、抗体、抗体フラグメント、ビオチン、又はアビジ ン及びストレプトアビジンのようなビオチンに結合する物質、レセプターに特異 的に結合するアゴニストもしくはそれらのアンタゴニスト、特異的ペプチド及び 蛋白質、レセプター、酵素、酵素基質、ヌクレオチド、リボ核酸、デオキシリボ 核酸、炭水化物、又はリポ蛋白質であることを特徴とする請求項18,19,23又は 24のいずれかに記載の方法。 27.受精、組織適合性、アレルギー学、感染学、衛生学、遺伝学、ウィルス学 、細菌学、毒物学、病理学、環境分析又は医療診断における請求項1〜17又は20 〜22のいずれかに記載の方法の使用。 28.受精、組織適合性、アレルギー学、感染学、衛生学、遺伝学、ウィルス学 、細菌学、毒物学、病理学、環境分析又は医療診断における請求項18,19又は23 に記載の化合物の使用。 29.構造特異的物質との強磁性もしくはフェリ磁性物質の組合せ又は請求項1 〜17又は20〜22のいずれかに記載の方法で同定されるべき被検体との強磁性もし くはフェリ磁性物質の組合せの使用。 30.ヒトの体内に導入される強磁性又はフェリ磁性コロイド状粒子を磁気緩和 測定で検出するための方法であって、前記粒子の磁化のネール緩和が、磁場を除 去した後に測定されることを特徴とする方法。 31.免疫マグネトグラフィーの方法であって、構造特異的物質が、最初に、 i)フェリ磁性又は強磁性コロイド状粒子で標識され、次に ii)これらの標識された構造特異的物質が生きている生物内に導入され、関心 の生物の容量が外部から適用される磁場により磁化され、そして前記外部からの 場が除去された後、磁気マーカーの磁化の緩和が磁場センサーにより測定される ことを特徴とする方法。 32.前記構造特異的物質が、抗体、抗体フラグメント、ビオチン、又はアビジ ンもしくはストレプトアビジンのようなビオチンに特異的に結合する物質、レセ プターに特異的に結合するアゴニストもしくはそれらのアンタゴニスト、特異的 ペプチド及び蛋白質、レセプター、酵素、酵素基質、ヌクレオチド、リボ核酸、 デオキシリボ 核酸、炭水化物、又はリポ蛋白質であることを特徴とする請求項30又は31に記載 の方法。 33.前記レセプターに結合するアゴニストが、サイトカイン、リンホカイン、 又はエンドセリンであることを特徴とする請求項22に記載の方法。 34.前記構造特異的物質が、105〜1015(mol/l)-1の範囲の結合定数を有する ことを特徴とする請求項32又は33に記載の方法。 35.前記構造特異的物質が、107〜1015(mol/l)-1の範囲の結合定数を有する ことを特徴とする請求項32又は33に記載の方法。 36.磁場センサーとして、超電導量子干渉計(SQUID)、誘導コイル、フラック スゲート(flux gate)磁力計、巨大磁気抵抗センサー、又は磁気抵抗性コンバー ターが用いられることを特徴とする請求項30〜35のいずれかに記載の方法。 37.緩和測定のかわりに、振動数の関数としての複合体磁化率の測定が評価の ために用いられることを特徴とする請求項30〜36のいずれかに記載の方法。 38.請求項30〜37のいずれかに記載の方法における請求項17又は21〜24のいず れかに記載の化合物の使用。 39.請求項30〜37のいずれかに記載の方法における構造特異的物質との強磁性 又はフェリ磁性物質の組合せの使用。 40.構造特異的物質との生分解可能フェリ磁性又は強磁性物質の組合せからな ることを特徴とする請求項30〜37のいずれかに記載の方法に用いるための化合物 。 41.構造特異的物質との生分解可能フェリ磁性又は強磁性物質の組合せからな り、それにより体液中での体温での構造特異的物質との前記フェリ磁性又は強磁 性物質の組合せのブラウン緩和時間が、ネール緩和時間より短いことを特徴とす る請求項30〜37のいずれか に記載の方法に用いるための化合物。 42.前記フェリ磁性又は強磁性物質が生分解可能な酸化鉄であることを特徴と する請求項41に記載の化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19503664A DE19503664C2 (de) | 1995-01-27 | 1995-01-27 | Magnetorelaxometrische Detektion von Analyten |
DE19503664.6 | 1995-01-27 | ||
PCT/EP1996/000339 WO1996023227A1 (de) | 1995-01-27 | 1996-01-29 | Verfahren und verbindungen zur magnetorelaxometrischen detektion von analyten und deren verwendung |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10513551A true JPH10513551A (ja) | 1998-12-22 |
JP3607297B2 JP3607297B2 (ja) | 2005-01-05 |
Family
ID=7753173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52263896A Expired - Fee Related JP3607297B2 (ja) | 1995-01-27 | 1996-01-29 | 被検体の磁気緩和測定での検出のための方法及び化合物並びにそれらの使用 |
Country Status (22)
Country | Link |
---|---|
US (2) | US6027946A (ja) |
EP (1) | EP0805983B1 (ja) |
JP (1) | JP3607297B2 (ja) |
KR (1) | KR100412006B1 (ja) |
CN (1) | CN1176001A (ja) |
AT (1) | ATE188778T1 (ja) |
AU (1) | AU703069B2 (ja) |
CA (1) | CA2211364A1 (ja) |
DE (2) | DE19503664C2 (ja) |
DK (1) | DK0805983T3 (ja) |
ES (1) | ES2142569T3 (ja) |
FI (1) | FI973122A0 (ja) |
GR (1) | GR3033138T3 (ja) |
HU (1) | HU221748B1 (ja) |
IL (1) | IL116915A (ja) |
NO (1) | NO973444D0 (ja) |
NZ (1) | NZ301665A (ja) |
PT (1) | PT805983E (ja) |
RU (1) | RU2176393C2 (ja) |
UA (1) | UA54384C2 (ja) |
WO (1) | WO1996023227A1 (ja) |
ZA (1) | ZA96625B (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003524781A (ja) * | 2000-02-04 | 2003-08-19 | アメリカ合衆国 | 磁性粒子用高性能磁気センサ |
JP2007538252A (ja) * | 2004-05-18 | 2007-12-27 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 生体検知において信号対バックグランド比を向上する磁気的な回転 |
JP2009534649A (ja) * | 2006-04-19 | 2009-09-24 | イメゴ アーベー | 検出のための装置及び方法 |
US7993581B2 (en) | 2004-03-11 | 2011-08-09 | Hitachi, Ltd. | Immunoassay system and immunoassay method |
JP4817581B2 (ja) * | 2000-03-09 | 2011-11-16 | マグニセンス・テクノロジー・リミテツド | 磁性粒子を用いた生物学的および/または化学的混合物の分析 |
US8193003B2 (en) | 2007-05-17 | 2012-06-05 | Hitachi, Ltd. | Method and system for detection of biomaterials using magnetic marker |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19503664C2 (de) * | 1995-01-27 | 1998-04-02 | Schering Ag | Magnetorelaxometrische Detektion von Analyten |
DE19508772C2 (de) * | 1995-03-01 | 1998-01-29 | Schering Ag | Verfahren und Verbindungen zur Detektion von Analyten mittels Remanenzmessung und deren Verwendung |
DE19615254C2 (de) * | 1996-04-18 | 1999-03-11 | Diagnostikforschung Inst | Gerät zur höchstempfindlichen magnetischen Detektion von Analyten |
WO1998018497A2 (en) * | 1996-10-28 | 1998-05-07 | Nycomed Imaging As | Contrast agents |
US6437563B1 (en) * | 1997-11-21 | 2002-08-20 | Quantum Design, Inc. | Method and apparatus for making measurements of accumulations of magnetically susceptible particles combined with analytes |
EP1198712A2 (de) * | 1999-02-17 | 2002-04-24 | Kilian Hennes | Verfahren zum darstellen von biologisch aktivierten induktivitätsändernden partikeln sowie vorrichtung dafür |
JP4171139B2 (ja) * | 1999-07-21 | 2008-10-22 | 住友電気工業株式会社 | 磁性体標識による免疫検査方法とその装置 |
EP1200825B1 (de) * | 1999-08-06 | 2005-08-24 | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin | Relaxation der doppelbrechung magnetischer nanopartikel während bindungsreaktionen |
US6979574B1 (en) * | 1999-08-06 | 2005-12-27 | Institut Fuer Diagnostik Forshung Gmbh | Process for detecting binding reactions with use of the measurement of the relaxation of the double refraction of magnetic particles |
DE19938372A1 (de) * | 1999-08-09 | 2001-03-08 | Diagnostikforschung Inst | Verfahren und Vorrichtung zur Trennung magnetischer Teilchen |
US6825655B2 (en) * | 2001-08-31 | 2004-11-30 | Imego Ab | Method and arrangement for detecting changes of a magnetic response in magnetic particles |
US20030076087A1 (en) * | 2001-08-31 | 2003-04-24 | Imego Ab | Method and arrangement relating to substance analysis |
JP4184268B2 (ja) | 2001-08-31 | 2008-11-19 | イメゴ アーベー | 物質を分析するための方法と構成 |
EP1300684A1 (en) * | 2001-10-08 | 2003-04-09 | Barts and The London National Health Service Trust | Homogenous ligand binding assay |
US8697029B2 (en) * | 2002-04-18 | 2014-04-15 | The Regents Of The University Of Michigan | Modulated physical and chemical sensors |
GB0215185D0 (en) * | 2002-07-01 | 2002-08-07 | Genovision As | Binding a target substance |
US20040157219A1 (en) * | 2003-02-06 | 2004-08-12 | Jianrong Lou | Chemical treatment of biological samples for nucleic acid extraction and kits therefor |
KR20060052889A (ko) * | 2003-07-30 | 2006-05-19 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | 생체 활성 분자 사이의 결합을 결정하기 위한 자기 입자의사용 |
US8060179B1 (en) | 2006-11-16 | 2011-11-15 | Scientific Nanomedicine, Inc. | Biomagnetic detection and treatment of Alzheimer's Disease |
US8118754B1 (en) | 2007-11-15 | 2012-02-21 | Flynn Edward R | Magnetic needle biopsy |
US20050239091A1 (en) * | 2004-04-23 | 2005-10-27 | Collis Matthew P | Extraction of nucleic acids using small diameter magnetically-responsive particles |
JP5053089B2 (ja) * | 2004-08-03 | 2012-10-17 | ベクトン・ディキンソン・アンド・カンパニー | 化合物の直接単離および多成分サンプルの分別のための磁性材料の使用 |
US7719265B2 (en) * | 2004-11-17 | 2010-05-18 | Honda Motor Co., Ltd. | Methods for determining particle size of metal nanocatalyst for growing carbon nanotubes |
US9964469B2 (en) | 2005-02-28 | 2018-05-08 | Imagion Biosystems, Inc. | Magnetic needle separation and optical monitoring |
US20080093219A1 (en) * | 2005-03-15 | 2008-04-24 | Tufts University | Magnetic Protein Nanosensors and Methods of Use |
US20070020699A1 (en) * | 2005-07-19 | 2007-01-25 | Idexx Laboratories, Inc. | Lateral flow assay and device using magnetic particles |
US7767404B2 (en) * | 2005-08-16 | 2010-08-03 | Chipotle Business Group, Inc. | Apparatus and method for single-step immunosorbent assay for single and multiple analytes |
US8735142B2 (en) * | 2005-08-16 | 2014-05-27 | Chipotle Business Group, Inc. | Systems and methods for immunosorbent assays for single and multiple analytes |
DE102006003177A1 (de) * | 2006-01-23 | 2007-08-02 | Siemens Ag | Vorrichtung und Verfahren zum Nachweis eines Analyten |
US8447379B2 (en) | 2006-11-16 | 2013-05-21 | Senior Scientific, LLC | Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof |
US9068977B2 (en) * | 2007-03-09 | 2015-06-30 | The Regents Of The University Of Michigan | Non-linear rotation rates of remotely driven particles and uses thereof |
AT503845B1 (de) | 2007-04-11 | 2008-03-15 | Arc Austrian Res Centers Gmbh | Optische messverfahren zur molekularen detektion anhand von relaxationsmessungen in optisch anisotropen nanopartikeln |
DK2171098T3 (en) * | 2007-06-29 | 2018-05-22 | Becton Dickinson Co | PROCEDURES FOR EXTRACTION AND CLEANING COMPONENTS IN BIOLOGICAL SAMPLES |
EP2217928B1 (en) * | 2007-12-04 | 2017-08-09 | Pacific Biosciences of California, Inc. | Alternate labeling strategies for single molecule sequencing |
DE102008013997B4 (de) | 2008-03-13 | 2012-10-31 | Bundesrepublik Deutschland, vertr. durch d. Bundesministerium f. Wirtschaft und Technologie, dieses vertreten durch d. Präsidenten d. Physikalisch-Technischen Bundesanstalt | Verfahren zum quantitativen Nachweis von Analyten in flüssigem Medium |
US8241854B2 (en) * | 2008-05-22 | 2012-08-14 | California Institute Of Technology | Triggered RNAi |
US9167983B2 (en) * | 2008-08-15 | 2015-10-27 | The University Of Houston System | Imaging method for obtaining spatial distribution of nanoparticles in the body |
US20110076782A1 (en) * | 2009-09-28 | 2011-03-31 | International Business Machines Corporation | Read-after-write detection of analytes via nanoparticle-labeled substances |
CN102695473B (zh) | 2009-11-06 | 2015-09-23 | 纳米医学科学公司 | 使用靶向纳米粒子及其磁特性的细胞如癌细胞和其他生物物质的检测、测量和成像 |
US10194825B2 (en) | 2009-11-06 | 2019-02-05 | Imagion Biosystems Inc. | Methods and apparatuses for the localization and treatment of disease such as cancer |
US8846331B2 (en) | 2010-08-27 | 2014-09-30 | The Regents Of The University Of Michigan | Asynchronous magnetic bead rotation sensing systems and methods |
US8409807B2 (en) | 2010-10-22 | 2013-04-02 | T2 Biosystems, Inc. | NMR systems and methods for the rapid detection of analytes |
ES2576927T3 (es) * | 2010-10-22 | 2016-07-12 | T2 Biosystems, Inc. | Sistemas de RMN y métodos para la detección rápida de analitos |
DE102010043276A1 (de) * | 2010-11-03 | 2012-05-03 | Siemens Aktiengesellschaft | Magnetische Zelldetektion |
US9304130B2 (en) | 2010-12-16 | 2016-04-05 | International Business Machines Corporation | Trenched sample assembly for detection of analytes with electromagnetic read-write heads |
US9816993B2 (en) | 2011-04-11 | 2017-11-14 | The Regents Of The University Of Michigan | Magnetically induced microspinning for super-detection and super-characterization of biomarkers and live cells |
US9040311B2 (en) | 2011-05-03 | 2015-05-26 | International Business Machines Corporation | Calibration assembly for aide in detection of analytes with electromagnetic read-write heads |
US8855957B2 (en) | 2011-05-03 | 2014-10-07 | International Business Machines Corporation | Method for calibrating read sensors of electromagnetic read-write heads |
RU2497128C2 (ru) * | 2011-12-30 | 2013-10-27 | Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Сибирский Федеральный Университет" | Способ одновременного определения двух аналитов биолюминесцентным молекулярным микроанализом |
US20130289383A1 (en) * | 2012-04-27 | 2013-10-31 | Edward R. Flynn | Magnetic Relaxometry using Brownian Randomization, Neel Relaxation, or Combinations Thereof |
US9797817B2 (en) | 2012-05-03 | 2017-10-24 | The Regents Of The University Of Michigan | Multi-mode separation for target detection |
US9435800B2 (en) | 2012-09-14 | 2016-09-06 | International Business Machines Corporation | Sample assembly with an electromagnetic field to accelerate the bonding of target antigens and nanoparticles |
US9983110B2 (en) | 2013-11-04 | 2018-05-29 | The Regents Of The University Of Michigan | Asynchronous magnetic bead rotation (AMBR) microviscometer for analysis of analytes |
US10338029B2 (en) * | 2014-12-10 | 2019-07-02 | General Electric Company | Systems and methods for improved physiological monitoring |
CN104614513B (zh) * | 2015-01-26 | 2016-05-25 | 国家纳米科学中心 | 一种基于磁分离的弛豫时间免疫传感分析方法 |
US10595957B2 (en) * | 2015-06-04 | 2020-03-24 | Endomagnetics Ltd | Marker materials and forms for magnetic marker localization (MML) |
DE102015225849A1 (de) * | 2015-12-18 | 2017-06-22 | Robert Bosch Gmbh | Verfahren zum Nachweis von Partikeln in einer Probe, Nachweisvorrichtung und mikrofluidisches System zum Untersuchen einer Probe |
US11519016B2 (en) | 2016-01-21 | 2022-12-06 | T2 Biosystems, Inc. | NMR methods and systems for the rapid detection of bacteria |
CN106518598A (zh) * | 2016-10-09 | 2017-03-22 | 大连理工大学 | 采用n、n‑二甲基乙酰胺溶剂纯化正己烷的装置及方法 |
WO2019068204A1 (en) * | 2017-10-06 | 2019-04-11 | Jin Zhang | BIOCATORS BASED ON GIANT MAGNETORESISTANCE |
CN111208287B (zh) * | 2020-01-16 | 2022-07-26 | 长沙理工大学 | 一种磁共振传感器的构建方法 |
US11136543B1 (en) | 2020-02-11 | 2021-10-05 | Edward R. Flynn | Magnetic cell incubation device |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863713A (en) * | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
JP2938918B2 (ja) * | 1990-01-25 | 1999-08-25 | ティーディーケイ株式会社 | 磁気微粒子の粒度測定方法 |
GB9007408D0 (en) * | 1990-04-02 | 1990-05-30 | Nycomed As | Compositions |
US5164297A (en) * | 1990-05-03 | 1992-11-17 | Advanced Magnetics Inc. | Solvent mediated relaxation assay system |
GB9120508D0 (en) * | 1991-09-26 | 1991-11-06 | Nycomed As | Diagnostic agents |
DE4309333A1 (de) * | 1993-03-17 | 1994-09-22 | Silica Gel Gmbh | Superparamagnetische Teilchen, Verfahren zu ihrer Herstellung und Verwendung derselben |
DE19503664C2 (de) * | 1995-01-27 | 1998-04-02 | Schering Ag | Magnetorelaxometrische Detektion von Analyten |
-
1995
- 1995-01-27 DE DE19503664A patent/DE19503664C2/de not_active Expired - Fee Related
-
1996
- 1996-01-26 ZA ZA96625A patent/ZA96625B/xx unknown
- 1996-01-26 IL IL11691596A patent/IL116915A/xx not_active IP Right Cessation
- 1996-01-29 DK DK96902934T patent/DK0805983T3/da active
- 1996-01-29 JP JP52263896A patent/JP3607297B2/ja not_active Expired - Fee Related
- 1996-01-29 NZ NZ301665A patent/NZ301665A/xx unknown
- 1996-01-29 PT PT96902934T patent/PT805983E/pt unknown
- 1996-01-29 CN CN96191613A patent/CN1176001A/zh active Pending
- 1996-01-29 DE DE59604171T patent/DE59604171D1/de not_active Expired - Lifetime
- 1996-01-29 US US08/875,418 patent/US6027946A/en not_active Expired - Fee Related
- 1996-01-29 UA UA97084369A patent/UA54384C2/uk unknown
- 1996-01-29 EP EP96902934A patent/EP0805983B1/de not_active Expired - Lifetime
- 1996-01-29 RU RU97114745/14A patent/RU2176393C2/ru not_active IP Right Cessation
- 1996-01-29 HU HU9702463A patent/HU221748B1/hu not_active IP Right Cessation
- 1996-01-29 KR KR1019970705107A patent/KR100412006B1/ko not_active Expired - Fee Related
- 1996-01-29 CA CA002211364A patent/CA2211364A1/en not_active Abandoned
- 1996-01-29 AT AT96902934T patent/ATE188778T1/de not_active IP Right Cessation
- 1996-01-29 WO PCT/EP1996/000339 patent/WO1996023227A1/de active IP Right Grant
- 1996-01-29 AU AU47149/96A patent/AU703069B2/en not_active Ceased
- 1996-01-29 ES ES96902934T patent/ES2142569T3/es not_active Expired - Lifetime
-
1997
- 1997-07-25 FI FI973122A patent/FI973122A0/fi not_active IP Right Cessation
- 1997-07-25 NO NO973444A patent/NO973444D0/no not_active Application Discontinuation
-
1999
- 1999-09-03 US US09/389,223 patent/US6485985B1/en not_active Expired - Fee Related
-
2000
- 2000-04-04 GR GR20000400831T patent/GR3033138T3/el not_active IP Right Cessation
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003524781A (ja) * | 2000-02-04 | 2003-08-19 | アメリカ合衆国 | 磁性粒子用高性能磁気センサ |
JP4817581B2 (ja) * | 2000-03-09 | 2011-11-16 | マグニセンス・テクノロジー・リミテツド | 磁性粒子を用いた生物学的および/または化学的混合物の分析 |
US7993581B2 (en) | 2004-03-11 | 2011-08-09 | Hitachi, Ltd. | Immunoassay system and immunoassay method |
JP2007538252A (ja) * | 2004-05-18 | 2007-12-27 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 生体検知において信号対バックグランド比を向上する磁気的な回転 |
JP2009534649A (ja) * | 2006-04-19 | 2009-09-24 | イメゴ アーベー | 検出のための装置及び方法 |
US8624584B2 (en) | 2006-04-19 | 2014-01-07 | Acreo Swedish Ict Ab | Method and arrangement relating to analyses of a substance |
US8193003B2 (en) | 2007-05-17 | 2012-06-05 | Hitachi, Ltd. | Method and system for detection of biomaterials using magnetic marker |
Also Published As
Publication number | Publication date |
---|---|
HUP9702463A3 (en) | 2000-03-28 |
US6485985B1 (en) | 2002-11-26 |
NO973444L (no) | 1997-07-25 |
MX9705543A (es) | 1997-10-31 |
AU4714996A (en) | 1996-08-14 |
KR100412006B1 (ko) | 2005-09-30 |
CA2211364A1 (en) | 1996-08-01 |
RU2176393C2 (ru) | 2001-11-27 |
DE59604171D1 (de) | 2000-02-17 |
NZ301665A (en) | 1999-03-29 |
DE19503664C2 (de) | 1998-04-02 |
EP0805983A1 (de) | 1997-11-12 |
IL116915A (en) | 2000-12-06 |
NO973444D0 (no) | 1997-07-25 |
ATE188778T1 (de) | 2000-01-15 |
US6027946A (en) | 2000-02-22 |
HUP9702463A2 (hu) | 1998-04-28 |
DK0805983T3 (da) | 2000-04-25 |
PT805983E (pt) | 2000-04-28 |
KR19980701711A (ko) | 1998-06-25 |
JP3607297B2 (ja) | 2005-01-05 |
IL116915A0 (en) | 1996-05-14 |
HU221748B1 (hu) | 2002-12-28 |
EP0805983B1 (de) | 2000-01-12 |
CN1176001A (zh) | 1998-03-11 |
ES2142569T3 (es) | 2000-04-16 |
FI973122L (fi) | 1997-07-25 |
GR3033138T3 (en) | 2000-08-31 |
WO1996023227A1 (de) | 1996-08-01 |
DE19503664A1 (de) | 1996-08-01 |
AU703069B2 (en) | 1999-03-11 |
ZA96625B (en) | 1997-07-21 |
FI973122A0 (fi) | 1997-07-25 |
UA54384C2 (uk) | 2003-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3607297B2 (ja) | 被検体の磁気緩和測定での検出のための方法及び化合物並びにそれらの使用 | |
Otieno et al. | Bioconjugation of antibodies and enzyme labels onto magnetic beads | |
US10488408B2 (en) | Detection of target molecules in a sample by using a magnetic field | |
US7033841B1 (en) | Process and compounds for use in detecting analytes by measurement of residual magnetism, and the use of the said compounds | |
JP2003528289A (ja) | 磁性粒子の二重屈折の緩和の測定を利用する結合反応を検出するための方法 | |
US20020123079A1 (en) | Process for detecting or quantifying a biological rreaction using superparamagnetic label | |
US20030124745A1 (en) | Process for detecting or quantifying a biological reaction using superparamagnetic label | |
CA2027035A1 (en) | Method for immunochemical determination of hapten | |
JP2005043049A (ja) | 超常磁性標識を用いて生物学的反応を検出または定量する方法 | |
MXPA97005543A (en) | Processes and compounds for magnetorrelaxometric detection of analytics and its |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040113 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040223 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040414 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040907 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20041007 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |